Cosmo Bio CompanyLimited Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Cosmo Bio CompanyLimited şirketinin toplam hissedar öz sermayesi ¥9.8B ve toplam borcu ¥20.0M olup, bu da borç-öz sermaye oranını 0.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥11.7B ve ¥2.0B dir. Cosmo Bio CompanyLimited 'in FAVÖK'ü ¥386.0M faiz karşılama oranı -5.1 dur. Şirketin ¥3.2B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

0.2%

Borç/özkaynak oranı

JP¥20.00m

Borç

Faiz karşılama oranı	-5.1x
Nakit	JP¥3.22b
Eşitlik	JP¥9.78b
Toplam yükümlülükler	JP¥1.96b
Toplam varlıklar	JP¥11.74b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Cosmo Bio CompanyLimited's (TSE:3386) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 12

Cosmo Bio CompanyLimited (TYO:3386) Is Experiencing Growth In Returns On Capital

May 09

Cosmo Bio Company,Limited (TYO:3386) Vies For A Place In Your Dividend Portfolio: Here's Why

Mar 23

Cosmo Bio Company,Limited's (TYO:3386) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02

Will The ROCE Trend At Cosmo Bio CompanyLimited (TYO:3386) Continue?

Feb 07

Does Cosmo Bio CompanyLimited's (TYO:3386) Share Price Gain of 30% Match Its Business Performance?

Jan 17

Should Cosmo Bio Company,Limited (TYO:3386) Be Part Of Your Dividend Portfolio?

Dec 23

Do Fundamentals Have Any Role To Play In Driving Cosmo Bio Company,Limited's (TYO:3386) Stock Up Recently?

Dec 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 3386 'nin kısa vadeli varlıkları ( ¥7.2B ) kısa vadeli yükümlülüklerini ( ¥976.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 3386 şirketinin kısa vadeli varlıkları ( ¥7.2B ) uzun vadeli yükümlülüklerini ( ¥979.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 3386 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 3386 'nin borç/öz sermaye oranı son 5 yılda 0.3% seviyesinden 0.2% seviyesine düştü.

Borç Kapsamı: 3386 'nin borcu işletme nakit akışı ( 990% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 3386 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Cosmo Bio CompanyLimited Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Cosmo Bio Company,Limited to Report Q3, 2024 Results on Nov 07, 2024

Cosmo Bio CompanyLimited's (TSE:3386) Shareholders Have More To Worry About Than Only Soft Earnings

Second quarter 2024 earnings released: EPS: JP¥4.79 (vs JP¥16.64 in 2Q 2023)

Cosmo Bio Company,Limited (TSE:3386) announces an Equity Buyback for 400,000 shares, representing 6.83% for ¥300 million.

Upcoming dividend of JP¥14.00 per share

Cosmo Bio Company,Limited to Report Q2, 2024 Results on Aug 05, 2024

First quarter 2024 earnings released: EPS: JP¥39.42 (vs JP¥45.41 in 1Q 2023)

Cosmo Bio Company,Limited to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: EPS: JP¥75.83 (vs JP¥89.06 in FY 2022)

Cosmo Bio Company,Limited, Annual General Meeting, Mar 26, 2024

Upcoming dividend of JP¥16.00 per share at 3.1% yield

Cosmo Bio Company,Limited to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings released: EPS: JP¥0.86 (vs JP¥8.08 in 3Q 2022)

Cosmo Bio Company,Limited to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings released: EPS: JP¥16.64 (vs JP¥7.06 in 2Q 2022)

Upcoming dividend of JP¥14.00 per share at 3.2% yield

Cosmo Bio Company,Limited to Report Q2, 2023 Results on Aug 04, 2023

First quarter 2023 earnings released: EPS: JP¥45.58 (vs JP¥63.19 in 1Q 2022)

Full year 2022 earnings released: EPS: JP¥89.06 (vs JP¥127 in FY 2021)

Full year 2022 earnings released: EPS: JP¥89.06 (vs JP¥127 in FY 2021)

Upcoming dividend of JP¥20.00 per share

Cosmo Bio Company,Limited to Report Fiscal Year 2022 Results on Feb 14, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: JP¥8.08 (vs JP¥21.58 in 3Q 2021)

Cosmo Bio Company,Limited to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: EPS: JP¥7.06 (vs JP¥27.13 in 2Q 2021)

Upcoming dividend of JP¥16.00 per share

Cosmo Bio Company,Limited to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: EPS: JP¥63.19 (vs JP¥56.78 in 1Q 2021)

Less than half of directors are independent

Cosmo Bio Company,Limited to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Cosmo Bio Company,Limited, Annual General Meeting, Mar 23, 2022

Upcoming dividend of JP¥24.00 per share

Third quarter 2021 earnings released: EPS JP¥21.58 (vs JP¥21.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥27.13 (vs JP¥36.78 in 2Q 2020)

Upcoming dividend of JP¥12.00 per share

First quarter 2021 earnings released: EPS JP¥56.78 (vs JP¥39.14 in 1Q 2020)

Cosmo Bio CompanyLimited (TYO:3386) Is Experiencing Growth In Returns On Capital

Full year 2020 earnings released: EPS JP¥114 (vs JP¥39.98 in FY 2019)

Cosmo Bio Company,Limited (TYO:3386) Vies For A Place In Your Dividend Portfolio: Here's Why

Cosmo Bio Company,Limited's (TYO:3386) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Full year 2020 earnings released: EPS JP¥114 (vs JP¥39.98 in FY 2019)

New 90-day high: JP¥1,330

Will The ROCE Trend At Cosmo Bio CompanyLimited (TYO:3386) Continue?

New 90-day high: JP¥1,314

Does Cosmo Bio CompanyLimited's (TYO:3386) Share Price Gain of 30% Match Its Business Performance?

Should Cosmo Bio Company,Limited (TYO:3386) Be Part Of Your Dividend Portfolio?

Upcoming Dividend of JP¥26.00 Per Share

New 90-day low: JP¥1,135

Cosmo Bio Company,Limited to Report Fiscal Year 2020 Final Results on Feb 12, 2021

Do Fundamentals Have Any Role To Play In Driving Cosmo Bio Company,Limited's (TYO:3386) Stock Up Recently?

Third quarter 2020 earnings released: EPS JP¥21.09

Third quarter 2020 earnings released: EPS JP¥21.09

New 90-day low: JP¥1,140

Cosmo Bio Company,Limited to Report Q3, 2020 Results on Nov 06, 2020

First half earnings released

Earnings released

New 90-day high - JP¥1,328

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin